MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Danaher Corporation Market Cap 2011-2026 | DHR
As of April 15, 2026 Danaher Corporation has a market cap of $ 142 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Danaher Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 B | 152 B | 183 B | 181 B | 196 B | 155 B | 121 B | 76.4 B | 70.7 B | 55.5 B | 45.9 B | 43.9 B | 39.7 B | 31.5 B | 26.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 196 B | 26.9 B | 102 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 19.89 | 10.93 % | $ 211 M |  China |
 |
Agilent Technologies
A
|
42 B | $ 120.39 | 2.46 % | $ 36.6 B |  USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.63 | 4.75 % | $ 939 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 1.38 | -4.83 % | $ 1.84 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 24.37 | 3.57 % | $ 677 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 179.31 | 0.54 % | $ 8.89 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 130.32 | 2.65 % | $ 20.7 B | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 520.0 | 3.74 % | $ 15 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 16.02 | 4.71 % | $ 484 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 29.09 | 1.89 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
13.4 B | $ 86.4 | 5.1 % | $ 10.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B | Niderland |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.91 | 6.97 % | $ 455 M | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.88 | 1.05 % | $ 93.5 K | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.1 | 0.96 % | $ 4.82 M | USA |
 |
Senseonics Holdings
SENS
|
351 M | $ 6.75 | 0.45 % | $ 282 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 113.06 | 2.44 % | $ 9.33 B |  Irlanda |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.35 | 4.38 % | $ 1.07 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 268.87 | 1.78 % | $ 22.4 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 120.85 | 0.37 % | $ 5.65 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.61 | 5.14 % | $ 2.08 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 82.74 | 1.31 % | $ 5.58 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 194.16 | 0.65 % | $ 21.6 B | USA |
 |
Natera
NTRA
|
5.31 B | $ 214.64 | 6.31 % | $ 21.1 B | USA |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 4.96 | -4.43 % | $ 3.9 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.04 | 1.34 % | $ 381 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |